Laurence Alexander

“I just wanted to flesh out one of the comments you made earlier about the pipeline you're seeing in terms of investments from your customers and visibility. When you look out to 2028, do you see any factors that would make 2028 a more difficult year than 2027?”

“So can you give a bit more detail about the underlying trends in the life sciences outlook and how that is setting you up for 2028-2029? I mean, should we think about this as a steady cadence where there are opportunities to shift your market share position over the next, say, three, four years?”

“So, given your progress with the DLE at the Atacama, can you give your perspective on the attractiveness or not of projects elsewhere in Chile? What would you need to see for those to move up your priority list?”

“So, I wanted to touch on two things quickly, if possible. One is, does the merger open up scope for pruning or divestitures within your portfolio to accelerate the deleveraging?”

“Please go ahead. good morning can you touch on or give some detail on how you're thinking now about your m a pipeline you know how active is it um what are you seeing in terms of valuations are there strategic directions that you'd be open to considering um just you know what's your positioning on that well first what…”